QCIL Stock Overview
A pharmaceutical manufacturing company, produces treatments for HIV/AIDS, Malaria, Hepatitis, and other products in Uganda.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Quality Chemical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | USh55.00 |
| 52 Week High | USh70.00 |
| 52 Week Low | USh52.00 |
| Beta | -0.22 |
| 11 Month Change | -1.79% |
| 3 Month Change | 0% |
| 1 Year Change | -15.38% |
| 33 Year Change | -42.11% |
| 5 Year Change | -57.03% |
| Change since IPO | -79.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| QCIL | UG Pharmaceuticals | UG Market | |
|---|---|---|---|
| 7D | -1.8% | -0.8% | 3.8% |
| 1Y | -15.4% | 10.8% | 16.8% |
Return vs Industry: QCIL underperformed the UG Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: QCIL underperformed the UG Market which returned 16.8% over the past year.
Price Volatility
| QCIL volatility | |
|---|---|
| QCIL Average Weekly Movement | 1.1% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 1.8% |
| 10% most volatile stocks in UG Market | 3.3% |
| 10% least volatile stocks in UG Market | 0.6% |
Stable Share Price: QCIL has not had significant price volatility in the past 3 months.
Volatility Over Time: QCIL's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 362 | Ajay Pal | www.qcil.com |
Quality Chemical Industries Limited, a pharmaceutical manufacturing company, produces treatments for HIV/AIDS, Malaria, Hepatitis, and other products in Uganda. It offers antibacterials, anti-hypertensives, vasodilators, anti-emetics, antibiotics, and antidiabetics products; and Lamivudine/Tenofovir Disoproxil Fumarate, Dolutegravir, Efavirenz, and Zidovudine tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; Texavir and Zentair for the treatment of Hepatitis B; and Isoniazid/Pyridoxine Hydrochloride /Sulfamethoxazole Trimethoprim tablets for the treatment of tuberculosis.
Quality Chemical Industries Limited Fundamentals Summary
| QCIL fundamental statistics | |
|---|---|
| Market cap | USh200.86b |
| Earnings (TTM) | USh31.76b |
| Revenue (TTM) | USh265.34b |
6.3x
P/E Ratio0.8x
P/S RatioIs QCIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QCIL income statement (TTM) | |
|---|---|
| Revenue | USh265.34b |
| Cost of Revenue | USh162.42b |
| Gross Profit | USh102.92b |
| Other Expenses | USh71.16b |
| Earnings | USh31.76b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.70 |
| Gross Margin | 38.79% |
| Net Profit Margin | 11.97% |
| Debt/Equity Ratio | 0% |
How did QCIL perform over the long term?
See historical performance and comparison